Publications by authors named "Shinji Asada"

Claim this Profile
E
Estimating the impact of pill burden on health utilities in hemodialysis therapy.
Hiroo Shimoda, Masatomo Taniguchi, Suguru Yamamoto, Ataru Igarashi, Shin Tokunaga, Shinji Asada

Sci Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence to istradefylline in patients with Parkinson's disease: A group-based trajectory analysis.
Toshiki Fukasawa, Etsuro Nakanishi, Hiroo Shimoda, Katsumi Shinoda, Satoru Ito, Shinji Asada

J Neurol Sci· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world evidence on levodopa dose escalation in patients with Parkinson's disease treated with istradefylline.
Nobutaka Hattori, Daijiro Kabata, Shinji Asada, Tomoyuki Kanda, Takanobu Nomura

PLoS One· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism.
Masanori Tokumoto, Shin Tokunaga, Shinji Asada, Yuichi Endo, Noriaki Kurita

PLoS One· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism.
Takashi Shigematsu, Shinji Asada, Yuichi Endo, Takehisa Kawata, Masafumi Fukagawa

PLoS One· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients.
Fumihiko Koiwa, Shin Tokunaga, Shinji Asada, Yuichi Endo, Masafumi Fukagawa

Kidney Int Rep· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Efficacy of evocalcet in previously cinacalcet-treated secondary hyperparathyroidism patients," [ 2021; https://doi.org/10.1016/j.ekir.2021.08.020].
Fumihiko Koiwa, Shin Tokunaga, Shinji Asada, Yuichi Endo, Masafumi Fukagawa

Kidney Int Rep· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism.
Chihiro Kato, Naohiko Fujii, Chisato Miyakoshi, Shinji Asada, Yoshihiro Onishi

BMC Nephrol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study.
Shinji Asada, Keitaro Yokoyama, Chisato Miyakoshi, Shingo Fukuma, Yuichi Endo

Clin Exp Nephrol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis.
Takashi Shigematsu, Shinji Asada, Yuichi Endo, Takehisa Kawata, Masafumi Fukagawa

Int J Nephrol Renovasc Dis· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study.
Shinji Asada, Kazuki Yoshida, Shingo Fukuma, Takanobu Nomura, Michihito Wada

PLoS One· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan.
Tetsuhiro Tanaka, Masaomi Nangaku, Enyu Imai, Yoshiharu Tsubakihara, Masatoshi Kamai, Shinji Asada

Clin Exp Nephrol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan.
Tetsuhiro Tanaka, Masaomi Nangaku, Enyu Imai, Yoshiharu Tsubakihara, Masatoshi Kamai, Shinji Asada

Clin Exp Nephrol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Oxoadenosine induces cytotoxicity through intracellular accumulation of 2-oxo-ATP and depletion of ATP but not via the p38 MAPK pathway.
Shinji Asada, Eiko Ohta, Yoriko Akimoto, Nona Abolhassani, Daisuke Tsuchimoto

Sci Rep· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis